Results 151 to 160 of about 19,867 (255)

Inducible CRISPR/Cas systems in precision oncology: Current applications and future perspectives

Clinical and Translational Medicine, Volume 16, Issue 6, June 2026.
Inducible CRISPR/Cas systems enable spatiotemporal genome editing in precision oncology. Chemical, optical, physical, and microenvironmental stimuli provide distinct control strategies. Conditional activation may reduce off‐target exposure and basal nuclease activity.
Ziliang Ding, Yukun Wei, Yong Han, Pengfei Gu   +3 more
wiley   +1 more source

Oncolytic Viruses for Canine Cancer Treatment

, 2018
Oncolytic virotherapy has been investigated for several decades and is emerging as a plausible biological therapy with several ongoing clinical trials and two viruses are now approved for cancer treatment in humans.
Diana Sánchez, Alfredo Amador-Molina, Gabriela Cesarman-Maus, Marcela Lizano   +3 more
core   +1 more source

Immune Evasion in Ovarian Cancer Peritoneal Metastasis: Mechanisms and Biomarker‐Guided Therapeutic Matching

Journal of Cellular Physiology, Volume 241, Issue 6, June 2026.
This graphical abstract summarizes the major immune‐evasion mechanisms that limit immunotherapy efficacy in ovarian cancer peritoneal metastasis. Peritoneal dissemination is shaped by impaired antigen visibility, coordinated immune‐evasion modules within ascites and multicellular spheroids, checkpoint‐driven T‐cell exhaustion, suppressive tumor ...
Xiaodong Wang, Junjie Wang, Di Xiong, Songli Cui, Qianqian Wang, Yiping Huang, Gouping Ding, Yixuan Tang, Yeqian Feng   +8 more
wiley   +1 more source

Therapeutic Poxviruses Induce the Secretion of Immunostimulating and Anti‐Tumoral Extracellular Vesicles

Journal of Extracellular Vesicles, Volume 15, Issue 6, June 2026.
Immune cells infected by therapeutic poxviruses release increased amounts of extracellular vesicles bearing viral proteins and therapeutic payloads. Such EVs have the ability to activate a CD8+ T‐cell mediated antitumoral immune response and decrease tumor growth.
Lucas Walther, Vincent Mittelheisser, Marie‐Christine Claudepierre, Louis Bochler, Magali Rompais, Jules Deforges, Nathalie Silvestre, Annabel Larnicol, Christine Carapito, Eric Quémeneur, Jacky G Goetz, Karola Rittner, Vincent Hyenne   +12 more
wiley   +1 more source

Radiotherapy and Immune System Interactions Historical Perspectives and Clinical Advancements

Molecular Carcinogenesis, Volume 65, Issue 6, Page 649-664, June 2026.
ABSTRACT Radiotherapy (RT) has evolved significantly since its inception from treating benign conditions to becoming a cornerstone of cancer treatment. This review examines the complex interactions between RT and the immune system, highlighting its diverse effects on various immune cell populations, and exploring emerging strategies to enhance ...
Safiy Yahia, Ayman J. Oweida, Houda Bahig, Daniel Taussky   +3 more
wiley   +1 more source

Organoids: From Bench to Bedside Applications

MedComm, Volume 7, Issue 6, June 2026.
Organoids, as a groundbreaking biomedical research platform, utilize adult stem cells (ASCs), embryonic stem cells (ESCs), and induced pluripotent stem cells (iPSCs) as sources. By integrating specific growth and differentiation signals within an extracellular matrix (e.g., Matrigel), organoids guide cells to self‐assemble into three‐dimensional ...
Kelin Li, Rui Cao, Maochen Li, Zichao Tian, Huahao Fan, Bixia Hong, Xiaojuan Liu   +6 more
wiley   +1 more source

Oncolytic viruses cancer therapy

, 2008
Wild-type viruses with intrinsic oncolytic capacity in human includes DNA viruses like some autonomous parvoviruses and many RNA viruses. Recent advances in molecular biology have allowed the design of several genetically modified viruses, such as ...
Zeicher, Marc
core  

Regulation of Immune Checkpoints: From Molecular Mechanisms to Clinical Therapies

MedComm, Volume 7, Issue 6, June 2026.
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment by unleashing antitumor immunity. This review comprehensively examines the molecular mechanisms underlying key immune checkpoints—including PD‐1/PD‐L1, CTLA‐4, and TIM‐3—and their clinical applications.
Qintao Ge, Liu Yu, Jiahe Lu, Aihetaimujiang Anwaier, Xiyue Xiao, Yonghao Chen, Dingwei Ye, Hailiang Zhang, Wenhao Xu, Wenbin Dai   +9 more
wiley   +1 more source

The Expanding Landscape of Microbiota Medicine: Indications, Therapeutic Modalities, and the Path Towards Integrative Microbiome‐Targeting Healthcare

Microbiota Medicine Research, Volume 1, Issue 2, Page 63-89, June 2026.
ABSTRACT The growing recognition of the microbiome’s role in human health has propelled the emergence of microbiota medicine—a new discipline integrating microbiology, multi‐omics, and clinical science. Advances in sequencing, data integration, and interventions such as fecal microbiota transplantation (FMT) have transitioned the field from ...
Min Dai, Yisha Lin, Renyou Gan, Xiaotao Shen, Shin Young Park, Sunjae Lee, Qi Su   +6 more
wiley   +1 more source

Theranostic Advancements in Brain Cancer: Promising Approaches for Emerging Therapy

MedComm – Oncology, Volume 5, Issue 2, June 2026.
Strategies for improving intra‐arterial administration (A) and photodynamic therapy in brain cancer (B). Improving intra‐arterial (IA) administration and photodynamic therapy (PDT) for brain cancer involves enhancing tumor targeting and breaching the blood–brain barrier (BBB). Key strategies include super selective catheterization, using osmotic agents
Bipraban Khanra, Manoj Kumar Sarangi
wiley   +1 more source